Facilitating Innovative Nuclear Diagnostics Act of 2021

Hozzl · 2024-03-11T20:20:08Z

Explore the details of Senate Bill 2609 Facilitating Innovative Nuclear Diagnostics Act of 2021 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/11/2024, 8:20 PM

Congressional Summary of S 2609

Facilitating Innovative Nuclear Diagnostics Act of 2021

This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2022 and as adjusted based on a specified fee schedule factor in each year thereafter.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 2609

Bill S 2609 is currently in the status of Bill Introduced since August 4, 2021. Bill S 2609 was introduced during Congress 117 and was introduced to the Senate on August 4, 2021. Bill S 2609's most recent activity was Read twice and referred to the Committee on Finance. as of August 4, 2021

Bipartisan Support of Bill S 2609

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 2609

Primary Policy Focus

Health

Potential Impact Areas

- Health care costs and insurance

- Medical tests and diagnostic methods

- Medicare

- Radiation

Alternate Title(s) of Bill S 2609

A bill to amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, diagnostic radiopharmaceuticals under the Medicare hospital outpatient prospective payment system.

Facilitating Innovative Nuclear Diagnostics Act of 2021